Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma. (PubMed, Front Oncol) - Sep 30, 2026 - "Pivotal Phase III trials, ZUMA-7 and TRANSFORM, have established second-line CD19-directed CAR T-cell therapies (axi-cel and liso-cel) as standard of care for primary refractory or early-relapsing disease, displaying superior survival outcomes compared with salvage chemoimmunotherapy followed by autologous hematopoietic stem cells transplantation (auto-HSCT) which is now limited to late relapses. Allogeneic HSCT remains a niche consolidative strategy exclusively for fit patients lacking other therapeutic options. Moving forward, novel bioengineering approaches, including dual-targeting, memory-enriched and "armored" CARs, aim to overcome current resistance mechanisms and redefine future clinical practice."
Journal • Review • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Secondary Central Nervous System Lymphoma • Transplantation
|
|
Benedetto Bruno; Claudia Marinucci; Davide Camoirano; Enrico Amaducci; Federica Cavallo; Irene Dogliotti; Luisa Giaccone; Mattia D'Agostino; Michele Clerico; Michele Dicataldo
|